anti-CD33 CAR T cells therapy（iCell Gene Therapeutics）

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug Nameanti-CD33 CAR T cells therapy（iCell Gene Therapeutics）
Drug Alias Nameanti-CD33 CAR T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Myeloid cell surface antigen CD33
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesIcell Gene Therapeutics (Int'L) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesiCell Gene Therapeutics LLCNational Cancer InstituteiCar Bio Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A